Korea United Pharm held a seminar for medical professionals to launch its aspirin–clopidogrel combination, Clavixin Duo Capsule, in the Mongolian market.

Last Thursday, Korea United Pharm invited over 50 Mongolian cardiologists to the Ramada Hotel in Ulaanbaatar for a launch seminar on Clavixin Duo Capsule. The Korean drugmaker plans to pursue full-scale market entry in collaboration with its local partner, Tsakhiur Tumur.

At the seminar, Professor Sung Min-soo of the Department of Neurology at Gangnam Severance Hospital spoke about the unique advantages, clinical evidence, and Korean prescription data for Clavixin Duo Capsule. Professor Sung explained the latest treatment strategies for aspirin–clopidogrel combination therapy, along with the product's formulation advantages and its potential to improve patient compliance.

Korea United Pharm expects the seminar to enhance awareness among Mongolian medical professionals and increase prescription volume. Beyond Clavixin Duo Capsule, the company plans to expand its local market presence for key export items, including the influenza treatment Tamiselvir Capsule and the anti-inflammatory analgesic Clanza S Soft Capsule, as it gradually increases its export scale in Mongolia.

Mongolia's pharmaceutical import market reached $155.64 million in 2022, with steady growth over the past few years. Korea was the second-largest supplier, underscoring the importance of Korean exporters in this expanding market.